• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Tempus AI (TEM) Undervalued As Its Cancer Vaccine Collaboration Expands?

    Simply Wall St·10/16/2026 04:48:31
    语音播报

    Tempus AI (TEM) extended its work on intismeran autogene, announcing an expanded multi year collaboration to support potential commercialization of the cancer vaccine candidate through sample handling and next generation sequencing services.

    That expanded collaboration comes at a time when Tempus AI shares have been rebuilding momentum, with a 90 day share price return of 35.56% and a year to date share price return of 14.06%, even though the 1 year total shareholder return is down 21.85% from earlier levels.

    Compare Tempus AI's news driven momentum with hand picked peers by scanning the 34 healthcare AI stocks that are also building businesses around AI powered diagnostics and precision medicine.

    So is Tempus AI now priced for blue sky on intismeran autogene, or are investors still discounting the risks that come with losses and an early stage oncology bet? And what does the valuation say about which view holds up?

    Most Popular Narrative: 6% Undervalued

    Tempus AI last closed at $71.13, against a narrative fair value of $75.68. This frames the recent share price recovery as still leaving some potential upside on the table according to the most followed thesis.

    The market has also become more reasonable on valuation. After the recent pullback, the stock trades around 5.7x forward revenue while the underlying business is still expected to grow organically by roughly 25% in 2026. Importantly, analysts have not materially reduced expectations for 2027 and 2028, suggesting confidence that growth remains durable rather than a short-term AI hype cycle.

    See why 31 investors see Tempus AI as 6% undervalued.

    Result: Fair Value of $75.68 (UNDERVALUED)

    Still, the narrative could crack if Tempus AI struggles to turn its growing data platform into sustained profits, or if oncology partnerships disappoint expectations.

    Find out about the key risks to this Tempus AI narrative.

    Another View: Tempus AI Looks Expensive On Sales

    The most followed narrative sees Tempus AI as 6% undervalued, yet the market is already paying a P/S of 9x. The broader US Life Sciences group trades at 4.5x, and Tempus AI's own fair ratio is 8.4x, which leaves little margin for error if expectations slip.

    This gap suggests investors are already paying up for future execution rather than getting a clear bargain. The key question is whether Tempus AI can grow into that richer P/S without stretching your risk limits.

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:TEM P/S Ratio as at Oct 2026
    NasdaqGS:TEM P/S Ratio as at Oct 2026

    Next Steps

    Sentiment on Tempus AI is split, with enthusiasm for the oncology upside and concern about execution risk pulling in opposite directions. Move quickly, look through the numbers yourself and weigh both the 1 key reward and 3 important warning signs.

    Looking for more Tempus AI style investment ideas?

    If you only stop at Tempus AI, you risk missing other opportunities that match or even better suit your own risk, income, and quality preferences.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.